At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 62 enrolled
Drug / intervention
CNTO 328biological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study of CNTO 328, A Monoclonal Antibody Against Interleukin-6 (IL-6), in Patients With Hormone Refractory Prostate Cancer
In Brief
A Phase 2 clinical trial evaluating CNTO 328 for Prostate Cancer. Completed, enrolled 62 participants across 123 sites.
Detailed Summary
RATIONALE: Monoclonal antibodies, such as anti-IL-6 chimeric monoclonal antibody, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. PURPOSE: This phase II trial is studying how well anti-IL-6 chimeric monoclonal antibody works in treating patients with metastatic prostate cancer that did not respond to hormone therapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProstate Cancer
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)
Timeline
Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedFeb 2007
Enrollment StartApr 2007
Primary CompletionMay 2009
Study CompletionJul 2011
TodayJul 2026
First PostedFeb 12, 2007
Enrollment StartApr 1, 2007
Primary CompletionMay 1, 2009
Study CompletionJul 1, 2011
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 19.4 years ago
Interventions
CNTO 328biological